Literature DB >> 7124629

Randomized double-blind comparison of verapamil and nifedipine in chronic stable angina.

V B Subramanian, M J Bowles, N S Khurmi, A B Davies, E B Raftery.   

Abstract

A randomized double-blind crossover trial was performed in 32 patients with chronic stable angina to compare the antianginal actions of verapamil (120 mg 3 times daily) and nifedipine (20 mg 3 times daily). Efficacy was assessed using objective end points obtained by computer-assisted exercise testing and 24 hour ambulatory monitoring for S-T segment shift. Twenty-eight patients completed the trial. The mean exercise time to produce angina improved from 5.7 +/- 0.3 minutes (mean +/- standard error of the mean) in patients on placebo, to 7.9 +/- 0.5 minutes in those on nifedipine and 10.0 +/- 0.7 minutes in those on verapamil. Similar improvement was seen in all other objective variables. Generally verapamil produced mild bradycardia and nifedipine mild tachycardia. Four patients complained of palpitations and angina after ingestion of nifedipine and were identified by ambulatory monitoring to have tachycardia and persistent S-T depression. These opposite effects on heart rate may explain the differences in efficacy between these 2 potent calcium ion antagonists.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7124629     DOI: 10.1016/0002-9149(82)91221-8

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  13 in total

Review 1.  Advancements in pharmacotherapy for angina.

Authors:  Ankur Jain; Islam Y Elgendy; Mohammad Al-Ani; Nayan Agarwal; Carl J Pepine
Journal:  Expert Opin Pharmacother       Date:  2017-03-15       Impact factor: 3.889

Review 2.  Nifedipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy, in ischaemic heart disease, hypertension and related cardiovascular disorders.

Authors:  E M Sorkin; S P Clissold; R N Brogden
Journal:  Drugs       Date:  1985-09       Impact factor: 9.546

3.  The efficacy and tolerance to three doses of diltiazem in elderly patients with stable angina.

Authors:  R L Logan
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

4.  An objective evaluation of once-daily sustained-release verapamil (480 mg) in chronic stable angina.

Authors:  E A Rodrigues; P DasGupta; A D Hains; E B Raftery
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

Review 5.  Calcium channel blocking agents and the heart.

Authors:  J Kenny
Journal:  Br Med J (Clin Res Ed)       Date:  1985-10-26

6.  Comparison of dihydropyridine and phenylalkylamine calcium antagonists in patients with coronary heart disease.

Authors:  G F Rettig; M Jakob; S Sen; A Heisel
Journal:  Drugs       Date:  1991       Impact factor: 9.546

7.  Effect of exercise training on the total ischaemic burden: an assessment by 24 hour ambulatory electrocardiographic monitoring.

Authors:  I C Todd; D Ballantyne
Journal:  Br Heart J       Date:  1992-12

Review 8.  Nicardipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy, in the treatment of angina pectoris, hypertension and related cardiovascular disorders.

Authors:  E M Sorkin; S P Clissold
Journal:  Drugs       Date:  1987-04       Impact factor: 9.546

9.  A randomized double-blind crossover study of nicardipine and nifedipine in patients with angina pectoris and concomitant essential hypertension.

Authors:  M Metra; S Nodari; G Nordio; L Bonandi; R Raddino; P Feroldi; L Dei Cas; O Visioli
Journal:  Cardiovasc Drugs Ther       Date:  1988-01       Impact factor: 3.727

10.  Exercise tolerance in angina is improved by mivazerol--an alpha 2-adrenoceptor agonist.

Authors:  R A Wright; P Decroly; T Kharkevitch; M F Oliver
Journal:  Cardiovasc Drugs Ther       Date:  1993-12       Impact factor: 3.727

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.